Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124020543 | 12402054 | 3 | F | 201510 | 20160706 | 20160525 | 20160712 | EXP | US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-32457BP | BOEHRINGER INGELHEIM | 75.35 | YR | F | Y | 99.79000 | KG | 20160712 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124020543 | 12402054 | 1 | PS | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | Respiratory (inhalation) | 18 MCG | 21395 | 18 | UG | INHALATION POWDER, HARD CAPSULE | QD | ||||||
| 124020543 | 12402054 | 2 | C | XARELTO | RIVAROXABAN | 1 | Oral | 20 MG | 0 | 20 | MG | TABLET | QD | ||||||
| 124020543 | 12402054 | 3 | C | EFFIENT | PRASUGREL HYDROCHLORIDE | 1 | Oral | 20 MG | 0 | 20 | MG | TABLET | QD | ||||||
| 124020543 | 12402054 | 4 | C | CARVEDILOL. | CARVEDILOL | 1 | Oral | 6.25 MG | 0 | 6.25 | MG | TABLET | QD | ||||||
| 124020543 | 12402054 | 5 | C | METOPROLOL TARTRATE. | METOPROLOL TARTRATE | 1 | Oral | 5 MG | 0 | 2.5 | MG | TABLET | BID | ||||||
| 124020543 | 12402054 | 6 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 40 MG | 0 | 40 | MG | TABLET | QD | ||||||
| 124020543 | 12402054 | 7 | C | CLONIDINE. | CLONIDINE | 1 | Oral | 0.2 MG | 0 | .1 | MG | TABLET | BID | ||||||
| 124020543 | 12402054 | 8 | C | DILTIAZEM. | DILTIAZEM | 1 | Oral | 240 MG | 0 | 240 | MG | CAPSULE | QD | ||||||
| 124020543 | 12402054 | 9 | C | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | Oral | 1 MG | 0 | 1 | MG | TABLET | QD | ||||||
| 124020543 | 12402054 | 10 | C | LEVEMIR | INSULIN DETEMIR | 1 | Subcutaneous | 25 MG | 0 | 25 | MG | QD | |||||||
| 124020543 | 12402054 | 11 | C | PRAVASTATIN. | PRAVASTATIN | 1 | Oral | 40 MG | 0 | 40 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124020543 | 12402054 | 1 | Chronic obstructive pulmonary disease |
| 124020543 | 12402054 | 2 | Product used for unknown indication |
| 124020543 | 12402054 | 3 | Product used for unknown indication |
| 124020543 | 12402054 | 4 | Product used for unknown indication |
| 124020543 | 12402054 | 5 | Product used for unknown indication |
| 124020543 | 12402054 | 6 | Product used for unknown indication |
| 124020543 | 12402054 | 7 | Hypertension |
| 124020543 | 12402054 | 8 | Product used for unknown indication |
| 124020543 | 12402054 | 9 | Diabetes mellitus |
| 124020543 | 12402054 | 10 | Diabetes mellitus |
| 124020543 | 12402054 | 11 | Blood cholesterol increased |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124020543 | 12402054 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124020543 | 12402054 | Cardiac failure congestive | |
| 124020543 | 12402054 | Lung neoplasm malignant | |
| 124020543 | 12402054 | Myocardial infarction | |
| 124020543 | 12402054 | Pneumonia | |
| 124020543 | 12402054 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124020543 | 12402054 | 1 | 2014 | 0 | ||
| 124020543 | 12402054 | 2 | 20160512 | 0 | ||
| 124020543 | 12402054 | 7 | 2011 | 0 |